93 results about "Predictive marker" patented technology

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.

Molecular markers useful in medicine response tests are provided, as an aid in determining whether an individual subject s tumor is responding to treatment with EGF and/or erbB2 inhibitors. Markers include phosphorylated ERK protein

The invention relates to tumor-related IncRNA and tumor-related IncRNA function predication. By taking differential expression of IncRNA in tumors as diagnosis references, a process for finding a relation between IncRNA and tumors includes: step one, downloading data from GEO database, processing the data to obtain expression data of part of IncRNA and exons; step two, subjecting the processed expression data to differential expression analysis; step three, analyzing co-expression and differential coding genes and IncRNA for IncRNA in differential expression; step four, subjecting the coding genes to probe platform annotation; step five, further screening the IncRNA in differential expression to select out most obviously differential IncRNA; step six, performing enrichment analysis to obtain a GOBP process and pathyway, and speculating IncRNA functions through coding gene related biological processes; step seven, analyzing whether common coding genes obtained at the step six can enter blood, saliva and urine or not, analyzing genes which are allowed to enter, and taking the genes and IncRNA as potential predication marks of cancers.

The application relates to improved means for the detection of soluble protein(s), such as soluble angiogenesis-related protein(s), more particularly circulating VE-cadherin. These means notably comprise the dilution of the fluid sample (e.g., serum or plasma sample), before submitting it to protein detection. Said dilution is advantageously diluted in a surfactant-containing solution. The improved means of the invention enabled to determine that circulating VE-cadherin is a reliable prognostic marker of the sensitivity or resistance to anti-tumoral treatment. It is believed that prior art sVE-cadherin detection means did not enable such determination.

The present invention provides a method of screening for markers useful in predicting the efficacy of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow up data. The present disclosure also provides methods of treating breast cancer that include screening a breast cancer patient for amplification of one or more of the genes disclosed herein, and treating a patient having amplification of one or more of these genes with a therapeutically effective amount of a compound that interferes with HER2 signaling.

The invention belongs to the technical field of the tumor medicine, and specifically discloses a gastric cancer prognosis predictive maker-ERICH3 protein and application of a detection reagent of theERICH3 protein in preparation of a kit or reagent for gastric cancer prognosis prediction. The detection reagent of the ERICH3 protein is used for detecting whether the ERICH3 protein is expressed molecule. By detecting the expression of the ERICH3 protein in a tissue sample, the lifetime of the gastric cancer patient can be effectively distinguished, thereby providing a new path for the judgementof the gastric cancer prognosis prediction and providing reference evidence for gastric cancer condition analysis by the clinician.

Embodiments of the invention are related to systems and methods for setting parameters of implantable medical devices, amongst other things. In an embodiment, the invention includes a method for programming an implantable medical device including sensing concentrations of a predictive marker such as ET-1 in a patient, selecting programming parameter values based on the sensed concentrations of the predictive marker, and implementing the selected programming parameter values. In an embodiment the invention includes a method for detecting arrhythmia in a patient including sensing concentrations of the predictive marker in a patient, selecting a level of stringency to be used in an arrhythmia detection module based on the sensed concentrations of the predictive marker, sensing electrical signals in the patient, and evaluating the sensed electrical signals for indicia of an arrhythmia using the arrhythmia detection module. Other embodiments are also included herein.

Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.

It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-α therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-α therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided. Further provided are methods of treating a patient diagnosed with HCC and expressing a low level of miR-26, wherein treatment comprises IFN-α therapy.

EMT signatures and markers useful for characterizing the status of epithelial cancers and for predicting drug responses in patients having non-small cell lung cancer are provided together with methods of using the same.

The invention discloses application of a PRMT5 gene serving as a marker for predicting, diagnosing and treating acute myocardial infarction and relates to peripheral blood acute myocardial infarction marker detection and application thereof. The PRMT5 gene or the expression product thereof is used as a new target for predicting, diagnosing and treating the acute myocardial infarction, the PRMT5 gene or the expression product thereof are used to prepare a preparation for predicting, diagnosing and treating the acute myocardial infarction, and important clinical application significance and a high development value are achieved.

The invention discloses a function-driven multi-molecular marker for individualized prediction of colorectal cancer prognosis and a device and an evaluation method thereof. Prognostic predictive markers are simultaneously screened from multiple cancer large sample data sets of multiple centers, and predictive effects of the multi-molecular marker are validated and comprehensively evaluated in three independent data sets. The application of the above methods and strategies ensures the reliability of the multi-molecular marker in judgment of the prognosis of a colorectal cancer patient; the multi-molecular marker combination is not affected by the batch effect of an experiment or the difference of a detection platform, thereby ensuring the stability of the multi-molecular marker in the judgment of the prognosis of the colorectal cancer patient; the multi-molecular marker combination does not need to be subjected to data standardization between multiple samples before use, thereby facilitating the use and ensuring the clinical operability of the multi-molecular marker in the judgment of the prognosis of the colorectal cancer patient.

Provided is a novel method for the early detection and/or discrimination of cancer and anti-cancer agents for the prevention or early treatment of cancer. In particular, the method relates to the determination of levels of circulating miRNAs in breast cancer patients, both primary and metastatic. Furthermore, kits, devices, pharmaceutical compositions as well as methods related thereto are described.

Methods and compositions are provided for the identification of a molecular diagnostic test for lung cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with NSCLC are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

The present invention provides a method of screening for markers useful in predicting the efficacy of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow up data. In addition, the present invention provides a method of treating breast cancer that includes measuring the expression levels or amplification of HTPAP in a patient having breast cancer and then providing a patient having increased levels of HTPAP expression or HTPAP amplification with therapeutic quantities of at least one compound that interferes with the phosphatidic acid phosphatase activity of HTPAP. The present invention also encompasses a method of treating breast cancer that includes screening a breast cancer patient for amplification of the cMYC gene and then treating a patient having amplification of the cMYC gene with therapeutic quantities of a compound that interferes with HER2 signaling.